Phase 2 trial data show lisocabtagene maraleucel achieved a 95% overall response rate in patients with relapsed or refractory marginal zone lymphoma, with a manageable safety profile and no new safety signals.
The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07538960 |
Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica. |
NOT_YET_RECRUITING | |
| NCT07388563 |
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma |
SUSPENDED | PHASE1 |
| NCT07356245 |
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma |
RECRUITING | PHASE2 |
| NCT06756308 |
A Study of Enasidenib in People With T-Cell Lymphoma |
RECRUITING | PHASE2 |
| NCT06550427 |
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing |
RECRUITING | |
| NCT06390319 |
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) |
RECRUITING | PHASE2 |
| NCT06224049 |
Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T |
RECRUITING | EARLY_PHASE1 |
| NCT06131801 |
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution |
RECRUITING | |
| NCT05996185 |
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma |
RECRUITING | PHASE2 |
| NCT05983965 |
Study of Tazemetostat in Lymphoid Malignancies |
TERMINATED | PHASE1 |
